-transparent.png){kind=logo}
A monoclonal antibody (mAb) generated against the chemically-induced BALB/c Meth A sarcoma, designated HD42, reacts in cytotoxic tests with Meth A as well as with BALB/c peripheral lymph node cells and mitogen-activated spleen cells. The antigen was detected by FACS analysis on BALB/c spleen and lymph node cells, and by absorption assays on all normal lymphoid cells of BALB/c but not B6 mice. The expression of the antigen was not found on normal adult lung fibroblasts, on brain, nor on an extensive panel of tumors of BALB/c and B6 origin. Because the strain distribution of the antigen is reciprocal to that of Ly-6.2 and is not expressed in congenic C3H.Ly-6b mice, we have tentatively defined it as Ly-6.1 and referred to the mAb as alpha-Ly-6.1. The presence of alpha-Ly-6.1 abrogates both the Con A-induced and the IL 2-dependent proliferative response of normal T cells, whereas the response of normal B cells to LPS remains unaffected. alpha-Ly-6.1 is a potent suppressor of the primary in vitro plaque-forming cell (PFC) response to SRBC. Pretreatment of normal splenic T cells with alpha-Ly-6.1 and complement had no effect on the ability of these cells to generate in vitro either T helper cells (TH) or T suppressor cells (TS) to SRBC. However, addition of antibody in the absence of complement during the generation of TH or TS, or posttreatment of these T cell subsets with antibody and complement after in vitro education, completely removed the functional activity of these cell types. Addition of alpha-Ly-6.1 to MLC suppressed the MLR as well as the generation of cytotoxic lymphocytes (CTL), whereas the presence of the antibody during a cell-mediated lympholysis (CML) had no effect. Therefore, it appears that alpha-Ly-6.1 recognizes an antigen that is important for the generation of TH and TS cell subsets.
P M Flood, and
D B Murphy, and
M Horowitz, and
K P LeClair, and
F R Smith, and
E Stockert, and
M A Palladino, and
A B DeLeo
October 1999,
Hybridoma,
P M Flood, and
D B Murphy, and
M Horowitz, and
K P LeClair, and
F R Smith, and
E Stockert, and
M A Palladino, and
A B DeLeo
April 1990,
Immunology,
P M Flood, and
D B Murphy, and
M Horowitz, and
K P LeClair, and
F R Smith, and
E Stockert, and
M A Palladino, and
A B DeLeo
April 1985,
Journal of immunology (Baltimore, Md. : 1950),
P M Flood, and
D B Murphy, and
M Horowitz, and
K P LeClair, and
F R Smith, and
E Stockert, and
M A Palladino, and
A B DeLeo
January 1992,
Archives of virology,
P M Flood, and
D B Murphy, and
M Horowitz, and
K P LeClair, and
F R Smith, and
E Stockert, and
M A Palladino, and
A B DeLeo
September 1986,
Infection and immunity,
P M Flood, and
D B Murphy, and
M Horowitz, and
K P LeClair, and
F R Smith, and
E Stockert, and
M A Palladino, and
A B DeLeo
September 1977,
Nature,
P M Flood, and
D B Murphy, and
M Horowitz, and
K P LeClair, and
F R Smith, and
E Stockert, and
M A Palladino, and
A B DeLeo
September 1985,
Journal of immunology (Baltimore, Md. : 1950),
P M Flood, and
D B Murphy, and
M Horowitz, and
K P LeClair, and
F R Smith, and
E Stockert, and
M A Palladino, and
A B DeLeo
May 1993,
Biochemical Society transactions,
P M Flood, and
D B Murphy, and
M Horowitz, and
K P LeClair, and
F R Smith, and
E Stockert, and
M A Palladino, and
A B DeLeo
September 1986,
Biochemical and biophysical research communications,
P M Flood, and
D B Murphy, and
M Horowitz, and
K P LeClair, and
F R Smith, and
E Stockert, and
M A Palladino, and
A B DeLeo
July 1988,
Japanese journal of cancer research : Gann,
